MannKind and United Snag Priority Review for Pulmonary Hypertension Drug

The U.S. Food and Drug Administration (FDA) has accepted for priority review MannKind’s and United Therapeutics’ New Drug Application (NDA) for Tyvaso DPI™, a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).